Clinical trials: Cholera
Cholera (Disorder)
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1.
- Trial name
- NCT03220737
- Testing
- VAXCHORA (Cholera Vaccine, Live, Oral)
- Where
- 10 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Enterotoxigenic Escherichia Coli Infection, Diarrhea
Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701
This is a single-center, double-blind, placebo-controlled, Phase II vaccination and challenge study designed to confirm a human challenge model with E. coli strain LSN03-016011/A.
- Trial name
- NCT03576183
- Testing
- VLA1701, Challenge Strain
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Cholera
A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic
The aim of the study is to generate safety and immunogenicity data with Shanchol in The Philippines Objectives: To describe the safety after each dose of Shanchol vaccine.
- Trial name
- NCT02434822
- Testing
- Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
- Where
- Dominican Republic
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cholera
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
Demonstrate that the vaccine offers protection based on antibody levels in older adults and is similar to antibody levels in adults aged 18-45 following vaccination with PXVX0200.
- Trial name
- NCT02100631
- Testing
- PXVX0200
- Where
- 16 sites in United States
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Cholera
A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines
The aim of the study is to generate safety and immunogenicity data with Oral Cholera Vaccine (Shanchol™) in The Philippines Objectives: To describe the safety after each dose of Shanchol vaccine.
- Trial name
- NCT01949675
- Testing
- Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
- Where
- 2 sites in Philippines
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cholera
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
The purpose of the study is to determine if PXVX0200 is safe and effective in preventing cholera infection
- Trial name
- NCT01895855
- Testing
- PXVX0200
- Where
- 3 sites in United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Cholera
To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131)
A Phase III randomized, modified double-blind, multi-centric, comparative study, to evaluate the non-inferiority of immunogenicity and safety of single strain oral cholera vaccine Hillchol® (BBV131) to the comparator vaccine…
- Trial name
- Hillchol131 (NCT05732766)
- Testing
- Hillchol vaccine
- Where
- 9 sites in India
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Cholera
Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera
Cholera still remains a global public health concern affecting both children and adults, and patients can succumb in quick time if remain untreated.
- Trial name
- NCT06193408
- Testing
- VR-AD-1005
- Where
- Bangladesh
- Volunteers
- 150 people
- Sponsor
- Hunazine Biotech S.L.
Cholera
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
The primary goal of this Phase III study is to compare 3 lots for consistency of manufacture.
- Trial name
- NCT02094586
- Testing
- PXVX0200 Lot A, PXVX0200 Lot B, PXVX0200 Lot C
- Where
- 25 sites in United States, Australia
- Volunteers
- 3,146 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Diarrhea, Infantile
Efficacy and Safety of "VS002A" With the Standard WHO-ORS in Non-cholera Acute Watery Diarrhea in Infants and Young Children
Randomized double blinded clinical trial comparing amino acid based oral rehydration solution/medical food and glucose-based oral rehydration solution is infectious diarrhea in pediatric population
- Trial name
- NCT04677296
- Testing
- VS002A, WHO-ORS
- Where
- Bangladesh
- Volunteers
- 312 people
- Sponsor
- Entrinsic Bioscience Inc.
Diarrhea
A Post-marketing Observational Study of Oral Cholera Vaccine
Chinese survey data indicate that the incidence rate of diarrhea in the general population ranges from 0.17 to 0.70 episodes per person-year, whereas among children under five years of age, the rate is significantly higher…
- Trial name
- NCT07300462
- Testing
- Recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules)
- Where
- 5 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Shanghai United Cell Biotechnology Co., Ltd
Prevention Harmful Effects
To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men
To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men
- Trial name
- OCV (NCT01707537)
- Testing
- Euvichol
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Cholera
A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131).
A Phase III randomized, modified double-blind, multi-centric, comparative study, to evaluate the noninferiority of immunogenicity and safety of single strain oral cholera vaccine Hillchol® (BBV131) to the comparator vaccine…
- Trial name
- Hillchol (NCT05507229)
- Testing
- Hillchol vaccine, Shanchol Vaccine
- Where
- 11 sites in India
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Cholera
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200
The purpose of this study is to compare the safety and immunogenicity of a single dose of the PXVX0200 live cholera vaccine versus placebo in volunteers (Vaccinees) and whether PXVX0200, which is a live attenuated bacteria, can…
- Trial name
- NCT01585181
- Testing
- PXVX0200
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic